Fertility treatments overview: types, how they work, and choosing the right option

When fertility treatment may be considered

Infertility is commonly defined as not achieving pregnancy after 12 months of regular, unprotected intercourse, or after 6 months when the person trying to conceive is age 35 or older. Evaluation may be recommended sooner if there are known risk factors, such as absent or very irregular periods, prior pelvic inflammatory disease, suspected endometriosis, recurrent pregnancy loss, previous cancer treatment, known tubal disease, or abnormal semen analysis.

A fertility evaluation typically aims to answer several questions: Is ovulation occurring? Are the fallopian tubes open? Is the uterus anatomically suitable for implantation and pregnancy? Are sperm concentration, motility, and morphology adequate? Are there endocrine, genetic, immunologic, or lifestyle factors that may affect the probability of conception?

Common components may include menstrual and ovulation history, pelvic ultrasound, ovarian reserve testing such as anti-Müllerian hormone and antral follicle count, hormonal testing when indicated, hysterosalpingography or other tubal assessment, uterine cavity evaluation, and semen analysis. Male-factor assessment is important because sperm-related factors contribute to a substantial proportion of infertility cases, either alone or in combination with female factors.

Lifestyle optimization and timed intercourse

Some people begin with optimizing natural conception attempts, especially when age, history, and initial testing suggest a reasonable chance of spontaneous pregnancy. This may include identifying the fertile window, timing intercourse around ovulation, starting folic acid or a prenatal vitamin, moderating alcohol intake, avoiding tobacco and recreational drugs, reviewing medications, managing chronic conditions, and working toward a sustainable weight range when medically relevant.

Fertility tracking methods can include menstrual cycle pattern recognition, cervical mucus observation, urinary luteinizing hormone testing, and sometimes basal body temperature charting. These methods do not treat infertility directly, but they may improve timing and help identify clues such as anovulation or short luteal phases. If cycles are highly irregular, prolonged, or absent, ovulation-focused evaluation is often more useful than continued tracking alone.

Expectant management has limits. Age-related decline in oocyte quantity and quality, significant tubal disease, severe endometriosis, and severe sperm abnormalities may reduce the usefulness of waiting. A clinician can help estimate whether continued natural attempts are reasonable or whether time-sensitive intervention is appropriate.

Fertility medicines and ovulation induction

Fertility medicines are commonly used when ovulation is irregular or absent, and sometimes to increase the number of eggs available in a treatment cycle. They work by influencing the hypothalamic-pituitary-ovarian axis or directly stimulating the ovaries.

• Oral ovulation induction medications: Agents such as letrozole or clomiphene citrate are used in many ovulatory disorders. They can promote follicular development and trigger more predictable ovulation. Monitoring may include ultrasound and hormone testing, depending on the clinical situation.
• Gonadotropin injections: Follicle-stimulating hormone and luteinizing hormone preparations directly stimulate the ovaries. They are used in some ovulation induction protocols, IUI cycles, and IVF cycles. They require careful monitoring because they can increase the risk of multiple follicles and multiple pregnancy.
• Ovulation trigger medications: Human chorionic gonadotropin or gonadotropin-releasing hormone agonist triggers may be used to time ovulation or egg maturation before retrieval.
• Luteal support: Progesterone may be used after certain treatments to support the uterine lining, especially in IVF protocols.

Medication choice depends on the diagnosis, ovarian reserve, body mass index, prior response, risk of ovarian hyperstimulation, and whether the cycle involves intercourse, IUI, or IVF. These medications should be used under medical guidance because dose, timing, and monitoring affect both safety and success.

Intrauterine insemination: how it works and when it may help

Intrauterine insemination, or IUI, places prepared sperm directly into the uterus around the time of ovulation. The semen sample is processed in a laboratory to concentrate motile sperm and remove seminal fluid. The insemination itself is usually a brief office procedure using a thin catheter passed through the cervix.

IUI may be considered for unexplained infertility, mild male-factor infertility, cervical-factor infertility, use of donor sperm, or situations where intercourse is difficult. It can be performed in a natural ovulatory cycle or combined with ovulation induction or ovarian stimulation.

The main advantage of IUI is that it is less invasive and less expensive than IVF. However, it still requires at least one open fallopian tube, reasonable sperm parameters after preparation, and ovulation. Its effectiveness is generally lower than IVF per cycle, and medicated IUI cycles can increase the chance of twins or higher-order multiples if too many follicles develop. Many clinics set cycle cancellation criteria to reduce this risk.

IVF and ICSI: the core assisted reproductive technology pathway

In vitro fertilization, or IVF, is the most widely recognized form of assisted reproductive technology. It bypasses several steps required for natural conception by retrieving eggs from the ovaries, fertilizing them in the laboratory, culturing embryos, and transferring an embryo into the uterus.

A typical IVF cycle includes several stages. First, ovarian stimulation uses injectable medications to recruit multiple follicles. Ultrasound and blood tests monitor follicle growth and hormone levels. When follicles are ready, a trigger medication promotes final egg maturation. Egg retrieval is then performed with transvaginal ultrasound guidance, usually under sedation. Eggs are fertilized with sperm by conventional insemination in the lab or by intracytoplasmic sperm injection, known as ICSI. Embryos are cultured for several days, often to the blastocyst stage. One embryo, or occasionally more depending on specific circumstances and guidelines, may be transferred into the uterus. Additional suitable embryos can be cryopreserved for future use.

ICSI is not a separate treatment cycle but a fertilization technique within IVF. In ICSI, an embryologist injects a single sperm directly into an egg. It is commonly considered when sperm concentration, motility, or morphology is significantly abnormal, when sperm must be surgically retrieved, after prior fertilization failure, or in some cases involving genetic testing or frozen oocytes.

IVF may be recommended when fallopian tubes are blocked or absent, after sterilization in some cases, with severe male-factor infertility, with diminished time for lower-intervention treatments due to age, after failed ovulation induction or IUI, in some endometriosis cases, when preimplantation genetic testing is being considered, or when donor eggs or a gestational carrier are needed.

Surgery, uterine treatment, and reproductive anatomy

Surgery may be part of fertility care when an anatomic factor is impairing conception or increasing miscarriage risk. The decision depends on whether correcting the abnormality is likely to improve outcomes compared with moving directly to assisted reproduction.

Examples include hysteroscopic removal of some endometrial polyps, submucosal fibroids, intrauterine adhesions, or a uterine septum; laparoscopic treatment of selected endometriosis; repair of some tubal problems; or treatment of varicocele in selected men with abnormal semen parameters. Surgery may also be used to retrieve sperm from the epididymis or testis when sperm are absent from the ejaculate because of obstruction or severely impaired production.

Not all abnormalities require surgery. For example, small fibroids that do not distort the uterine cavity may not meaningfully affect fertility, while hydrosalpinx can reduce IVF success and may be treated before embryo transfer. A fertility specialist can help weigh surgical risk, recovery time, age-related urgency, and expected benefit.

Donor eggs, donor sperm, donor embryos, and gestational carriers

Third-party reproduction may be considered when using a person’s own eggs, sperm, uterus, or embryos is not possible, not advisable, or not aligned with the family-building plan. These options can be emotionally complex and often involve medical, psychological, legal, ethical, and financial counseling.

• Donor sperm: May be used for severe male-factor infertility, single parents by choice, LGBTQ+ family building, or genetic-risk avoidance.
• Donor eggs: May be considered with markedly diminished ovarian reserve, premature ovarian insufficiency, age-related oocyte quality concerns, repeated IVF failure related to egg factors, or avoidance of certain genetic conditions.
• Donor embryos: May be an option when both egg and sperm donation are acceptable or when embryo donation aligns with personal values.
• Gestational carrier: May be considered when pregnancy is medically unsafe, the uterus is absent or unable to carry a pregnancy, or after certain repeated implantation or pregnancy complications. The carrier has no genetic link to the embryo unless a separate egg donation arrangement is involved.

Programs vary in screening, anonymity, legal requirements, infectious disease testing, genetic carrier screening, and counseling practices. Local laws differ considerably, so legal advice from professionals experienced in reproductive law is often essential.

Choosing the right option: a structured decision framework

There is rarely a universally correct treatment. A good decision is one that matches the medical evidence with your priorities and constraints. It can help to separate the decision into clinical, practical, and personal domains.

• Diagnosis: Tubal blockage, anovulation, severe sperm abnormalities, endometriosis, uterine cavity problems, and unexplained infertility often point toward different first-line strategies.
• Age and ovarian reserve: Time may be a major factor, especially in the late 30s and 40s or when ovarian reserve is low. Faster escalation to IVF may be discussed in these settings.
• Likelihood per cycle versus cumulative likelihood: IUI may have a lower per-cycle chance than IVF but may be reasonable over several cycles in selected patients. IVF may offer more information about egg number, fertilization, embryo development, and cryopreservation potential.
• Risk tolerance: Multiple pregnancy, ovarian hyperstimulation syndrome, procedure risks, medication side effects, and emotional stress differ by treatment.
• Financial and access considerations: Insurance coverage, medication costs, travel distance, monitoring visits, time off work, and laboratory fees can strongly influence choice.
• Values and boundaries: People differ in how they feel about embryo creation, genetic testing, donor gametes, freezing embryos, selective reduction, or stopping treatment.

Before starting, ask your clinician: What diagnosis are we treating? What are the reasonable alternatives? What is the estimated live birth rate for someone with my age and test results at this clinic? What are the cancellation criteria? How many embryos would be transferred? What complications should prompt urgent care? What are the total expected costs, including medications and storage?

Emotional health, treatment fatigue, and support

Fertility treatment can be physically demanding and emotionally intense. Monitoring appointments, injections, waiting periods, pregnancy tests, financial pressure, pregnancy announcements, and uncertainty can create a cycle of hope and grief. These reactions are not a sign that you are coping poorly; they are common responses to a high-stakes medical journey.

Support can include counseling with a fertility-informed mental health professional, peer support groups, clear communication with a partner if applicable, workplace planning, and setting boundaries around social events or conversations. Some people also find it helpful to decide in advance how many cycles they are willing to try before reassessing, while leaving room to revise that plan as new medical information emerges.

It is reasonable to pause or stop treatment if the burden becomes too high, even if additional options remain. It is also reasonable to pursue more intensive treatment if that aligns with your goals and medical advice. Fertility care should respect both reproductive autonomy and emotional wellbeing.